Proteinuria should be used as a surrogate in CKD

Paolo Cravedi, Piero Ruggenenti, Giuseppe Remuzzi

Research output: Contribution to journalReview articlepeer-review

107 Scopus citations

Abstract

Surrogate end points of renal failure are instrumental to the testing of new treatments in patients with chronic kidney disease, the natural history of which is characterized by a slow, asymptomatic decline in renal function. The magnitude of proteinuria is widely recognized as a marker of the severity of glomerulopathy. Population-based studies have identified proteinuria as a predictor of future decline in glomerular filtration rate and of the development of end-stage renal disease. More importantly, a reduction in proteinuria invariably translates into a protection from renal function decline in patients with diabetic and nondiabetic renal disease with overt proteinuria. Thus, proteinuria should be considered a valuable surrogate end point for clinical trials in patients with proteinuric renal diseases.

Original languageEnglish
Pages (from-to)301-306
Number of pages6
JournalNature Reviews Nephrology
Volume8
Issue number5
DOIs
StatePublished - May 2012
Externally publishedYes

Fingerprint

Dive into the research topics of 'Proteinuria should be used as a surrogate in CKD'. Together they form a unique fingerprint.

Cite this